3,5-di-(1-piperidinyl)toluene | 37708-76-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3,5-di-(1-piperidinyl)toluene
• 英文别名: 1,3-Dipiperidino-5-methylbenzol；3,5-Dipiperidyltoluol；3,5-Dipiperidinotoluol；1,1'-(5-methyl-m-phenylene)-bis-piperidine；1,1'-(5-Methylbenzene-1,3-diyl)dipiperidine；1-(3-methyl-5-piperidin-1-ylphenyl)piperidine
• CAS: 37708-76-2
• 化学式: C₁₇H₂₆N₂
• 分子量: 258.407
• InChiKey: JEQHZZNVQLPYGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  哌啶 、 3,5-二溴甲苯 在 bromopalladium(1+);N'-(naphthalen-1-ylmethylideneamino)carbamimidothioate;triphenylphosphane 、 potassium carbonate 作用下， 以 仲丁醇 为溶剂， 反应 24.0h， 以74.7%的产率得到3,5-di-(1-piperidinyl)toluene
  参考文献：
  名称：

  Synthesis and structural characterization of palladium(II) thiosemicarbazone complex: application to the Buchwald–Hartwig amination reaction

  摘要：

  A simple route to synthesize mononuclear palladium(II) thiosemicarbazone complex has been described. Elemental analysis, spectral methods and single crystal X-ray diffraction analysis were used to confirm the composition of the complex. The new complex acts as an active homogeneous catalyst for the Buchwald-Hartwig amination reaction of a wide range of aryl and heteroaryl halides (bromides and chlorides), including activating, neutral and deactivating substrates, with various secondary amines under optimized conditions. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2012.12.070

文献信息

• [EN] USES OF SATL-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS<br/>[FR] UTILISATIONS D'INHIBITEURS DE KINASE INDUCTIBLE PAR UN SEL (SIK) POUR TRAITER L'OSTÉOPOROSE
  申请人：MASSACHUSETTS GEN HOSPITAL

  公开号：WO2018053373A1

  公开（公告）日：2018-03-22

  The present disclosure provides methods of treating and/or preventing osteoporosis using salt-inducible kinase (SIK) inhibitors. Also provided are methods of using SIK inhibitors for increasing the function of osteocytes, increasing the number of osteoblasts, increasing the activity of osteoblasts, inhibiting the resorption of a bone, decreasing the number of osteoclasts, inhibiting the activity of osteoclasts, increasing the mass of a bone, down-regulating the expression of the gene SOST, and/or inhibiting the activity of sclerostin. The SIK inhibitors may be combined with Src inhibitors or CSF I R inhibitors. Exemplary SIK inhibitors include the compounds of the formula: (I), (II), (III), (IV), (V) or (VI).

  本公开提供了使用盐诱导激酶（SIK）抑制剂治疗和/或预防骨质疏松症的方法。还提供了使用SIK抑制剂增加成骨细胞功能、增加成骨细胞数量、增加成骨细胞活性、抑制骨骼吸收、减少破骨细胞数量、抑制破骨细胞活性、增加骨骼质量、下调SOST基因表达和/或抑制硬化蛋白活性的方法。SIK抑制剂可以与Src抑制剂或CSF I R抑制剂结合使用。典型的SIK抑制剂包括公式：（I）、（II）、（III）、（IV）、（V）或（VI）的化合物。